COMPLETED

Assessment of Hyperphosphorylated Tau PET Binding in Primary Progressive Aphasia and Frontotemporal Dementia

Talk to us

Conditions

Primary Progressive AphasiaBehavioral Variant of Frontotemporal DementiaFrontotemporal Dementia, Behavioral VariantPPAbvFTDFTD

Quick Navigation

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

This study is designed to learn more about overall tau burden in the brain of patients with Primary Progressive Aphasia (PPA) and Frontotemporal Dementia.

Official Title

Assessment of Hyperphosphorylated Tau PET Binding in Primary Progressive Aphasia and FTD

Quick Facts

Study Start:2016-07
Study Completion:2024-08-01
Study Type:Not specified
Phase:Not Applicable
Enrollment:Not specified
Status:COMPLETED

Study ID

NCT02736695

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:18 Years
Sexes Eligible for Study:ALL
Accepts Healthy Volunteers:No
Standard Ages:ADULT, OLDER_ADULT
Inclusion CriteriaExclusion Criteria
  1. * Must be over the age of 18
  2. * Must speak English as your primary language
  3. * Must have an informant who can provide independent evaluation of functioning
  4. * Must present with a chief complaint of progressive impairment of speech/language or changes in behavior
  5. * Must fulfill diagnostic criteria for Primary Progressive Aphasia or Frontotemporal Dementia
  1. * Any subject who is mute or whose speech is unintelligible will be excluded
  2. * All subjects with concurrent illnesses that could account for speech and language deficits, such as traumatic brain injury, strokes or developmental syndromes, and subjects meeting criteria for another neurodegenerative disease, such as amnestic Alzheimer's type dementia, dementia with Lewy bodies, progressive supranuclear palsy, and corticobasal syndrome will be excluded
  3. * All pregnant, post-partum and breast-feeding women will be excluded
  4. * Subjects will also be excluded if MRI is contraindicated (metal in head, cardiac pace maker, etc.), if there is severe claustrophobia, if there are conditions that may confound brain imaging studies (e.g. structural abnormalities, including subdural hematoma or intracranial neoplasm), or if they are medically unstable or are on medications that might affect brain structure or metabolism,(e.g. chemotherapy).

Contacts and Locations

Principal Investigator

Keith A Josephs, M.D.
PRINCIPAL_INVESTIGATOR
Mayo Clinic

Study Locations (Sites)

Mayo Clinic
Rochester, Minnesota, 55905
United States

Collaborators and Investigators

Sponsor: Mayo Clinic

  • Keith A Josephs, M.D., PRINCIPAL_INVESTIGATOR, Mayo Clinic

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2016-07
Study Completion Date2024-08-01

Study Record Updates

Study Start Date2016-07
Study Completion Date2024-08-01

Terms related to this study

Keywords Provided by Researchers

  • PPA
  • bvFTD
  • FTD

Additional Relevant MeSH Terms

  • Primary Progressive Aphasia
  • Behavioral Variant of Frontotemporal Dementia
  • Frontotemporal Dementia, Behavioral Variant